search
Back to results

Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode

Primary Purpose

End Stage Renal Disease

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
THERANOVA 400 dialyzer prototype AA
THERANOVA 400 dialyzer prototype BB
FX CorDiax 80 Dialyzer
FX CorDiax 800 Dialyzer
Sponsored by
Baxter Healthcare Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for End Stage Renal Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient has end-stage renal disease (Chronic kidney disease stage 5D)
  2. Patient is 18 years of age or older
  3. Patient is male or female
  4. Patient, if female, is non-pregnant; and if capable of becoming pregnant, will be using a medically acceptable means of contraception during participation in the study 5 .Patient has been receiving HD or HDF therapy for >3 months prior to study enrollment and is expected to survive for at least 12 months after enrollment.

6. Patient has a stable functioning native fistula 7. Patient is willing to comply with the study requirements for therapy during the entire study treatment period 8. Patient is capable fo providing written informed consent to participate in the study

Exclusion Criteria:

  1. Patient is undergoing single-needle dialysis
  2. Patient has an known abnormal k/λ ratio (less than 0.37, or greater than 3.1)
  3. Patient has a known active infection and is currently receiving antibiotic treatment
  4. Patient has known active cancer
  5. Patient has a known positive serology test for human immunodeficiency virus (HIV) or hepatitis B,C or E
  6. Patient has a known serious hemostasis disorder
  7. Patient has a known monoclonal gammopathy
  8. Patient has a known polyclonal gammopathy
  9. Patient has a unstable condition as judged by the treating physician based on medical history, physical examination and laboratory testing including (but not limited to) any of the following:

    • Myocardial infarction within the last 3 months
    • Tachyarrhythmia or bradyarrhythmia absoluta
    • Unstable angina pectoris
    • Left ventricular ejection fraction <30%
    • Significant pericardial disease
  10. Patient has any other known comorbidity that could, in the opinion of the Investigator, potentially conflict with the study purpose or procedure
  11. Patient has a known significant psychiatric disorder or mental disability that could interfere with the patient's ability to provide informed consent and/or comply with protocol procedures
  12. Patient has a history of non-compliance with the dialysis prescription, as assessed by the Investigator
  13. Patient has participated in another interventional clinical study in the past 3 months, or is currently participating in another interventional clinical study

Sites / Locations

  • Dialysexentrum Elsenfeld

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Active Comparator

Active Comparator

Arm Label

THERANOVA 400 dialyzer prototype AA

THERANOVA 400 dialyzer prototype BB

FX CorDiax 80 dialyzer

FX CorDiax 800 dialyzer

Arm Description

THERANOVA 400 dialyzer prototype AA in hemodialysis

THERANOVA 400 dialyzer prototype BB in hemodialysis

FX CorDiax 80 dialyzer in hemodialysis

FX CorDiax 800 dialyzer in high volume hemodiafiltration

Outcomes

Primary Outcome Measures

Overall clearance of lambda FLC clearance
Blood and dialysate
Overall albumin loss
Dialysate

Secondary Outcome Measures

Types and frequency of adverse events and device deficiencies as a measure of safety and dialyzer tolerability
All adverse events and device deficiencies will be recorded
Clearance of other middle sized molecules
Blood and dialysate
Hematology ( blood cell counts; hematocrit and hemoglobin)
Blood

Full Information

First Posted
February 3, 2015
Last Updated
February 17, 2022
Sponsor
Baxter Healthcare Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT02377622
Brief Title
Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode
Official Title
Comparison of the Clinical Performance of 2 THERANOVA 400 Dialyzer Prototypes in HD With a High-Flux Dialyzer in HD and a High-Flux Dialyzer in hvHDF - A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2015
Overall Recruitment Status
Completed
Study Start Date
February 2015 (undefined)
Primary Completion Date
April 2015 (Actual)
Study Completion Date
May 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baxter Healthcare Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study investigates the performance of a new dialyzer (Theranova 400) containing a membrane with increased pore sizes. The performance will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. Two different Theranova 400 prototypes (AA and BB) operated in hemodialysis mode will be compared with a Cordiax Fx-80 dialyzer, operated in hemodialysis mode, and with a Cordiax Fx-800, operated in high volume hemodiafiltration mode. Safety events and albumin loss into the dialysate will be monitored

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
THERANOVA 400 dialyzer prototype AA
Arm Type
Experimental
Arm Description
THERANOVA 400 dialyzer prototype AA in hemodialysis
Arm Title
THERANOVA 400 dialyzer prototype BB
Arm Type
Experimental
Arm Description
THERANOVA 400 dialyzer prototype BB in hemodialysis
Arm Title
FX CorDiax 80 dialyzer
Arm Type
Active Comparator
Arm Description
FX CorDiax 80 dialyzer in hemodialysis
Arm Title
FX CorDiax 800 dialyzer
Arm Type
Active Comparator
Arm Description
FX CorDiax 800 dialyzer in high volume hemodiafiltration
Intervention Type
Device
Intervention Name(s)
THERANOVA 400 dialyzer prototype AA
Intervention Type
Device
Intervention Name(s)
THERANOVA 400 dialyzer prototype BB
Intervention Type
Device
Intervention Name(s)
FX CorDiax 80 Dialyzer
Intervention Type
Device
Intervention Name(s)
FX CorDiax 800 Dialyzer
Primary Outcome Measure Information:
Title
Overall clearance of lambda FLC clearance
Description
Blood and dialysate
Time Frame
Five (5) hours ( for each mid-week dialysis session)
Title
Overall albumin loss
Description
Dialysate
Time Frame
Five (5) hours (for each mid-week dialysis session)
Secondary Outcome Measure Information:
Title
Types and frequency of adverse events and device deficiencies as a measure of safety and dialyzer tolerability
Description
All adverse events and device deficiencies will be recorded
Time Frame
Average 60 days (continuously, from signature of informed consent form until 1 week after last hemodialysis session with an experimental or active comparator product)
Title
Clearance of other middle sized molecules
Description
Blood and dialysate
Time Frame
Five (5) hours (for each mid-week dialysis session)
Title
Hematology ( blood cell counts; hematocrit and hemoglobin)
Description
Blood
Time Frame
Five (5) hours ( for each mid-week dialysis session)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient has end-stage renal disease (Chronic kidney disease stage 5D) Patient is 18 years of age or older Patient is male or female Patient, if female, is non-pregnant; and if capable of becoming pregnant, will be using a medically acceptable means of contraception during participation in the study 5 .Patient has been receiving HD or HDF therapy for >3 months prior to study enrollment and is expected to survive for at least 12 months after enrollment. 6. Patient has a stable functioning native fistula 7. Patient is willing to comply with the study requirements for therapy during the entire study treatment period 8. Patient is capable fo providing written informed consent to participate in the study Exclusion Criteria: Patient is undergoing single-needle dialysis Patient has an known abnormal k/λ ratio (less than 0.37, or greater than 3.1) Patient has a known active infection and is currently receiving antibiotic treatment Patient has known active cancer Patient has a known positive serology test for human immunodeficiency virus (HIV) or hepatitis B,C or E Patient has a known serious hemostasis disorder Patient has a known monoclonal gammopathy Patient has a known polyclonal gammopathy Patient has a unstable condition as judged by the treating physician based on medical history, physical examination and laboratory testing including (but not limited to) any of the following: Myocardial infarction within the last 3 months Tachyarrhythmia or bradyarrhythmia absoluta Unstable angina pectoris Left ventricular ejection fraction <30% Significant pericardial disease Patient has any other known comorbidity that could, in the opinion of the Investigator, potentially conflict with the study purpose or procedure Patient has a known significant psychiatric disorder or mental disability that could interfere with the patient's ability to provide informed consent and/or comply with protocol procedures Patient has a history of non-compliance with the dialysis prescription, as assessed by the Investigator Patient has participated in another interventional clinical study in the past 3 months, or is currently participating in another interventional clinical study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Torsten Böhler, Manager
Organizational Affiliation
Life Sciences & Operations, Gambro Dialysatoren GmbH (a subsidiary of Baxter International Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Dialysexentrum Elsenfeld
City
Elsenfeld
ZIP/Postal Code
63820
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
27587605
Citation
Kirsch AH, Lyko R, Nilsson LG, Beck W, Amdahl M, Lechner P, Schneider A, Wanner C, Rosenkranz AR, Krieter DH. Performance of hemodialysis with novel medium cut-off dialyzers. Nephrol Dial Transplant. 2017 Jan 1;32(1):165-172. doi: 10.1093/ndt/gfw310. Erratum In: Nephrol Dial Transplant. 2021 Jul 23;36(8):1555-1556.
Results Reference
result
PubMed Identifier
28910799
Citation
Kirsch AH, Rosenkranz AR, Lyko R, Krieter DH. Effects of Hemodialysis Therapy Using Dialyzers with Medium Cut-Off Membranes on Middle Molecules. Contrib Nephrol. 2017;191:158-167. doi: 10.1159/000479264. Epub 2017 Sep 14.
Results Reference
result

Learn more about this trial

Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode

We'll reach out to this number within 24 hrs